Haematologic Oncology
Clinical research is centred on lymphoma, with a specific focus on peripheral T-cell lymphomas and CD30-expressing disease.
- Peripheral T-cell lymphomas
- CD30-expressing malignancies
- Non-Hodgkin lymphoma
The sponsor’s activity is aligned with treatment development in blood cancers requiring targeted therapeutic strategies.
Targeted Antibody-Drug Therapy
Research interest includes brentuximab vedotin, a CD30-directed antibody-drug conjugate used in combination treatment for lymphoma.
- Antibody-drug conjugates
- CD30-targeted therapy
- Combination immunotherapy
This area reflects a therapeutic emphasis on targeted oncology for haematological cancers.
Frontline Lymphoma Treatment
The funded trial addresses treatment for previously untreated lymphoma, with attention to initial disease control in aggressive T-cell neoplasms.
- Initial treatment of lymphoma
- Previously untreated disease
- Aggressive T-cell malignancy
Clinical interest extends to improving therapeutic options in the first-line setting for patients with limited established choices.
Safety and Tolerability in Oncology
Alongside efficacy, the research portfolio includes assessment of safety and tolerability in cancer treatment combinations.
- Treatment safety
- Drug tolerability
- Oncology combination regimens
These interests support clinical evaluation of therapies intended for specialist lymphoma care.
